KRYS - Krystal Biotech, Inc.
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m.
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth. VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week.
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—especially oncology flagship KB707—and a $1B cash position supporting R&D without dilution risk. VYJUVEK's international rollout and pipeline catalysts could drive annual net income to $1.8–$2.9B, with forward PE potentially as low as 2.9–4.6.
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%. KRYS's robust balance sheet ($823M cash and negligible debt) and disciplined capital allocation fund a broad clinical pipeline without dilution risk. Two registrational readouts in 2026 and two more enrolling in 2027, position KRYS for significant pipeline-driven upside beyond Vyjuvek.
Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.2 per share a year ago.